Henry Meds LegitScript and Accreditation Status: An Independent Review

What Is LegitScript and Why Does It Matter for Telehealth Pharmacies?

LegitScript certification is an independent compliance standard that verifies whether an online pharmacy or telehealth prescriber meets legal and ethical requirements for dispensing prescription drugs over the internet. Google, Meta, and most major ad platforms require LegitScript certification before allowing online pharmacy advertising. The absence of certification does not automatically mean a company is operating illegally, but it does mean the company has not submitted to that particular third-party audit.

How LegitScript Evaluates Platforms

LegitScript reviews applicants against criteria that include valid state pharmacy licenses, a licensed prescriber in the patient's state, a legitimate patient-prescriber relationship, and compliance with the Ryan Haight Online Pharmacy Consumer Protection Act [1]. Companies that pass receive a "Certified" badge and are listed in the publicly searchable LegitScript database. Companies that have not applied, or that applied and were denied, do not appear in that certified list.

Henry Meds' Position in the LegitScript Database

A search of the LegitScript certified merchant database in July 2025 did not return Henry Meds as a certified telehealth platform or online pharmacy [2]. Henry Meds does not display a LegitScript badge on its website. This does not constitute proof of illegal operation, but it does mean patients cannot rely on that certification layer when evaluating the company. Patients should instead verify licensing through their own state's pharmacy board and the relevant medical board.

What Patients Should Check Instead

Because LegitScript certification is absent, patients evaluating Henry Meds should independently confirm three things: the dispensing pharmacy holds an active license in the patient's home state, the prescribing clinician holds an active license in that same state, and the compounding pharmacy is registered with the FDA as required under 21 U.S.C. § 503A or § 503B [3].

FDA Regulatory Status of Compounded Semaglutide

Compounded semaglutide is not FDA-approved. The FDA's position on compounded GLP-1 drugs shifted materially in early 2025, and patients using platforms like Henry Meds are directly affected.

The Drug Shortage Exemption and Its End

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of commercially available drugs when those drugs appear on the FDA drug shortage list [3]. Semaglutide (Ozempic, Wegovy) was placed on the shortage list in 2022. The FDA removed injectable semaglutide from the shortage list in February 2025 and set a compliance deadline of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities to stop producing compounded semaglutide [4].

FDA Enforcement Signals

The FDA's May 2025 guidance stated that compounded semaglutide that is "essentially a copy" of an FDA-approved drug may no longer be produced once the shortage resolves [4]. The agency noted it would take enforcement action on a risk-based basis. Patients who enrolled with Henry Meds or similar platforms during the shortage period may be receiving a product that now exists in a legally ambiguous state. The FDA has not issued a blanket recall of compounded semaglutide already dispensed, but new prescriptions filled after the compliance deadline carry regulatory risk [4].

503A vs. 503B: The Difference Patients Should Understand

503A pharmacies compound for individual patients based on a valid prescription [3]. 503B outsourcing facilities compound in larger quantities and are subject to current good manufacturing practice (cGMP) regulations and FDA facility registration [3]. Henry Meds has not publicly disclosed which specific compounding pharmacies fulfill its prescriptions. Patients should ask directly which pharmacy fills their order and verify that pharmacy's registration at FDA's drug establishment database [5].

Compounded Semaglutide: Clinical Efficacy and Safety Considerations

Compounded semaglutide is intended to mimic FDA-approved semaglutide formulations. The evidence base for efficacy comes from trials on branded semaglutide, not compounded versions.

STEP-1 Trial Data

In the STEP-1 trial (N=1,961), subcutaneous semaglutide 2.4 mg once weekly produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [6]. These results apply to Novo Nordisk's Wegovy formulation, which uses a specific inactive ingredient profile, a validated manufacturing process, and dose-escalation schedules that have been tested in humans. Compounded semaglutide is not bioequivalent-tested against Wegovy, and the FDA has not evaluated any compounded semaglutide for safety or efficacy [4].

SURMOUNT-1 Trial Data for Tirzepatide

Henry Meds also offers compounded tirzepatide. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo (P<0.001) [7]. Again, this evidence applies to Eli Lilly's Zepbound, not to compounded versions. Compounded tirzepatide carries the same lack of FDA-reviewed bioequivalence data as compounded semaglutide. Tirzepatide remains on the FDA shortage list as of mid-2025, which means 503A compounding of tirzepatide may still be legally permissible during that window [8].

Quality and Concentration Risks

The FDA issued a safety communication in 2024 noting reports of adverse events, including hospitalizations, associated with compounded semaglutide, some of which involved incorrect dosing due to concentration differences between compounded and branded formulations [9]. Compounded products may use semaglutide sodium or semaglutide acetate salt forms rather than the base semaglutide used in Wegovy, and the clinical significance of that difference has not been established in peer-reviewed trials [9].

Henry Meds BBB Profile and Patient Complaints

The Better Business Bureau (BBB) is a non-governmental consumer advocacy organization that tracks business accreditation and complaint records. Henry Meds is not accredited by the BBB as of July 2025 [10].

Complaint Patterns

BBB complaint data, which is publicly searchable, shows a pattern of complaints related to billing disputes, subscription cancellation difficulty, and delayed shipments [10]. These categories are common across telehealth subscription models and do not by themselves indicate clinical harm. Patients should nonetheless read the complaint responses carefully, because the resolution language in a company's BBB replies often reveals how it handles refund requests and prescription transfers.

What "Not Accredited" Means

BBB accreditation requires a business to pay a membership fee and agree to the BBB's Code of Business Practices [10]. Some legitimate companies simply choose not to apply. The absence of accreditation is not equivalent to a BBB rating of F. Henry Meds holds a BBB profile with a letter grade that patients can view directly on the BBB site. Patients should look at the volume of complaints, the nature of those complaints, and the company's response rate, not just the letter grade in isolation.

Trustpilot and Reddit Signals

Beyond the BBB, patient reviews on Trustpilot and Reddit threads (r/Semaglutide, r/Ozempic) describe mixed experiences with Henry Meds. Positive reviews frequently cite lower cost versus brand-name Wegovy, which carries a list price of approximately $1,349/month without insurance [11]. Negative reviews describe difficulty reaching customer support and confusion about medication concentration. These anecdotal signals are not clinical evidence, but they are relevant to a patient's experience of care.

State Pharmacy Board Licensing: How to Verify Henry Meds' Fulfilling Pharmacies

Every state requires a pharmacy that ships prescriptions to residents of that state to hold an active non-resident pharmacy license. The National Association of Boards of Pharmacy (NABP) maintains a database of state-licensed pharmacies and a separate ".pharmacy" accreditation program [12].

NABP's "Not Recommended" List

NABP also publishes a list of online pharmacies it does not recommend, based on violations of pharmacy laws and practice standards [12]. Patients should search that database for any pharmacy name that appears on their Henry Meds shipping label. The NABP list is updated regularly and covers both domestic and international non-compliant pharmacies.

Steps to Verify a Compounding Pharmacy

1. Ask Henry Meds support for the name and address of the compounding pharmacy filling your prescription.
2. Search that pharmacy's name in your state board of pharmacy license lookup tool.
3. Search the same pharmacy in the FDA's registered drug establishment database [5].
4. Check whether that pharmacy appears on the NABP "Not Recommended" list [12].

This four-step check takes under 15 minutes and provides a meaningful compliance baseline that LegitScript certification would otherwise supply.

Prescriber Licensing and the Patient-Prescriber Relationship

Henry Meds operates primarily through asynchronous telemedicine, meaning patients complete an intake questionnaire and a clinician reviews it without a live video call. Asynchronous prescribing is legal in many states but prohibited in others for controlled substances and, in some jurisdictions, for any new prescription.

Ryan Haight Act Considerations

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person evaluation before a controlled substance may be prescribed via the internet [13]. GLP-1 receptor agonists (semaglutide, tirzepatide) are not controlled substances, so the Ryan Haight Act does not directly apply to them. Many state medical boards have enacted their own telemedicine prescribing standards that may require a synchronous (live audio or video) evaluation before any new prescription, regardless of drug schedule [13].

Verifying Your Prescriber

Patients should confirm that the clinician whose name appears on their prescription holds an active license in their state. The Federation of State Medical Boards (FSMB) offers a free physician license verification tool at docinfo.org [14]. A prescription signed by a clinician not licensed in the patient's state may be invalid, and a pharmacy that fills such a prescription may be violating state law.

Pricing, Transparency, and Informed Consent

Henry Meds markets compounded semaglutide at a significantly lower price than branded Wegovy or Ozempic. The subscription model typically runs $297, $397/month depending on dose, compared with the $1,349/month list price of Wegovy [11]. That price differential is real and meaningful for patients without insurance coverage.

What the Price Difference Reflects

The lower price reflects several factors: the use of compounded rather than FDA-approved drug product, the absence of Novo Nordisk's manufacturing and trial costs in the price, and a direct-to-patient model that bypasses traditional pharmacy benefit managers. None of those factors are inherently problematic, but they are worth understanding explicitly.

Informed Consent Requirements

Patients considering compounded semaglutide should receive, at minimum, written disclosure that the product is not FDA-approved, that it has not been tested for bioequivalence to Wegovy, and that the FDA has raised safety concerns about compounded GLP-1 formulations [4][9]. The American Society of Health-System Pharmacists (ASHP) recommends that patients receiving compounded medications be counseled on the difference between compounded and FDA-approved drugs [15]. Whether Henry Meds provides that level of disclosure in its intake process is something patients should ask about directly before subscribing.

The framework below summarizes the verification steps a patient should complete before filling a compounded GLP-1 prescription through any cash-pay telehealth platform, including Henry Meds. The HealthRX medical team developed this checklist based on FDA guidance, NABP standards, and state telemedicine regulations reviewed in July 2025.

Pre-Enrollment Verification Framework for Compounded GLP-1 Telehealth

| Verification Step | Source to Check | Pass Criterion | |---|---|---| | Prescriber state license | FSMB docinfo.org | Active license in patient's state | | Pharmacy state license | State board of pharmacy | Active non-resident license | | FDA pharmacy registration | FDA drug establishment database | Registered 503A or 503B facility | | NABP standing | NABP online database | Not on "Not Recommended" list | | LegitScript status | LegitScript certified merchant search | Listed as Certified (optional but useful) | | FDA shortage list status | FDA drug shortages database | Drug on shortage list if compounded copy | | Informed consent disclosure | Company intake documentation | Written disclosure of non-FDA-approved status |

How Henry Meds Compares to Accredited Telehealth Competitors

Several telehealth companies that also offer compounded or branded GLP-1 medications hold LegitScript certification or NABP accreditation. Ro, Hims and Hers, and Calibrate, for example, have pursued LegitScript certification as part of their advertising compliance strategy [2]. That certification does not guarantee clinical superiority, and it does not mean their compounded products are FDA-approved either.

What Accreditation Does and Does Not Signal

LegitScript certification signals that a company met a compliance threshold at the time of audit. It does not guarantee that every prescription is clinically appropriate, that compounded drug quality is verified, or that billing practices are fair. A certified company can still receive BBB complaints. An uncertified company can still operate legally in its licensed states.

The Clinical Bottom Line on Platform Choice

Patients choosing between telehealth GLP-1 platforms should weigh certification status as one factor among several, alongside pharmacy verification, prescriber availability for follow-up questions, and whether the platform provides access to branded FDA-approved medications if the patient's clinical situation warrants it. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends FDA-approved agents as first-line when accessible [16]. When cost is the primary barrier, a verified compounding pharmacy under active 503A oversight may represent a reasonable alternative during periods when the drug appears on the FDA shortage list, but that window for semaglutide has now closed [4].

Key Takeaways for Patients Evaluating Henry Meds

Henry Meds is not listed as LegitScript certified as of July 2025. The FDA removed semaglutide from the drug shortage list in early 2025, which eliminated the primary legal basis for 503A compounding of semaglutide. Compounded tirzepatide retains a potential shortage-based exemption while it remains on the shortage list. Patients should run the four-step pharmacy verification check described above, confirm prescriber licensure via FSMB, and request written informed consent disclosure before enrolling.

The monthly price of $297, $397 is substantially below the $1,349 list price for branded Wegovy [11], but that savings comes with regulatory uncertainty that has materially increased since April 2025. Patients who have already enrolled and are receiving compounded semaglutide should speak with the prescribing clinician about transition options to FDA-approved semaglutide if insurance coverage becomes available or if the FDA escalates enforcement activity [4].